GSA Capital Partners LLP Invests $642,000 in AngioDynamics, Inc. (NASDAQ:ANGO)

Key Points

• GSA Capital Partners LLP acquired a new stake in AngioDynamics, Inc., purchasing 68,328 shares valued at approximately $642,000, which represents about 0.17% of the company.
• Several institutional investors, including JPMorgan Chase & Co. and American Century Companies Inc., have significantly increased their positions in AngioDynamics, highlighting strong interest in the company.
• AngioDynamics reported a quarterly revenue increase of 13.0% year-over-year, achieving $80.16 million and surpassing analysts' expectations while posting earnings of ($0.03) per share.

GSA Capital Partners LLP acquired a new position in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 68,328 shares of the medical instruments supplier's stock, valued at approximately $642,000. GSA Capital Partners LLP owned 0.17% of AngioDynamics as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of ANGO. Quinn Opportunity Partners LLC bought a new position in AngioDynamics during the fourth quarter valued at approximately $92,000. ProShare Advisors LLC bought a new position in AngioDynamics during the fourth quarter valued at approximately $100,000. Graham Capital Management L.P. bought a new position in AngioDynamics during the fourth quarter valued at approximately $106,000. OneDigital Investment Advisors LLC raised its position in AngioDynamics by 14.0% in the fourth quarter. OneDigital Investment Advisors LLC now owns 12,137 shares of the medical instruments supplier's stock worth $111,000 after acquiring an additional 1,490 shares during the period. Finally, Cerity Partners LLC raised its position in AngioDynamics by 22.0% in the first quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier's stock worth $121,000 after acquiring an additional 2,333 shares during the period. Hedge funds and other institutional investors own 89.43% of the company's stock.

AngioDynamics Price Performance

Shares of AngioDynamics stock traded down $0.17 during trading on Wednesday, hitting $8.50. The stock had a trading volume of 101,781 shares, compared to its average volume of 647,132. The firm's fifty day simple moving average is $9.74 and its 200-day simple moving average is $9.87. The stock has a market cap of $345.36 million, a PE ratio of -10.24 and a beta of 0.67. AngioDynamics, Inc. has a 12 month low of $5.83 and a 12 month high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings data on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.09. AngioDynamics had a negative net margin of 11.62% and a negative return on equity of 3.20%. The company had revenue of $80.16 million during the quarter, compared to analyst estimates of $74.26 million. During the same quarter last year, the business posted ($0.06) EPS. The firm's revenue for the quarter was up 13.0% on a year-over-year basis. Analysts expect that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ANGO. HC Wainwright restated a "buy" rating and set a $16.00 price objective on shares of AngioDynamics in a research report on Wednesday, July 16th. Canaccord Genuity Group raised their target price on shares of AngioDynamics from $15.00 to $17.00 and gave the company a "buy" rating in a research note on Wednesday, July 16th. Finally, Lake Street Capital initiated coverage on shares of AngioDynamics in a research note on Wednesday, July 16th. They set a "buy" rating and a $24.00 target price for the company.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.